Oral extended-release oxymorphone: a new choice for chronic pain relief.

Abstract

Opana ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the micro-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.

• Authors: Alan K Matsumoto
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 8 Issue 10 Pg. 1515-27 (Jul 2007) ISSN: 1744-7666 [Electronic] England
• PMID: 17661733 (Publication Type: Journal Article, Review)

Chemical References

• Analgesics, Opioid
• Delayed-Action Preparations
• Oxymorphone

Topics

• Administration, Oral
• Analgesics, Opioid (administration & dosage, adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Animals
• Chronic Disease
• Delayed-Action Preparations
• Drug and Narcotic Control
• Humans
• Oxymorphone (administration & dosage, adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Pain (drug therapy)
• Patient Selection
• Severity of Illness Index
• Treatment Outcome